Literature DB >> 30108951

Approaches to target tractability assessment - a practical perspective.

Kristin K Brown1, Michael M Hann2, Ami S Lakdawala3, Rita Santos4, Pamela J Thomas5, Kieran Todd5.   

Abstract

The assessment of the suitability of novel targets to intervention by different modalities, e.g. small molecules or antibodies, is increasingly seen as important in helping to select the most progressable targets at the outset of a drug discovery project. This perspective considers differing aspects of tractability and how it can be assessed using in silico and experimental approaches. We also share some of our experiences in using these approaches.

Year:  2018        PMID: 30108951      PMCID: PMC6072525          DOI: 10.1039/c7md00633k

Source DB:  PubMed          Journal:  Medchemcomm        ISSN: 2040-2503            Impact factor:   3.597


  51 in total

Review 1.  Predicting protein druggability.

Authors:  Philip J Hajduk; Jeffrey R Huth; Christin Tse
Journal:  Drug Discov Today       Date:  2005-12       Impact factor: 7.851

2.  Identifying and characterizing binding sites and assessing druggability.

Authors:  Thomas A Halgren
Journal:  J Chem Inf Model       Date:  2009-02       Impact factor: 4.956

3.  Drug-target network.

Authors:  Muhammed A Yildirim; Kwang-Il Goh; Michael E Cusick; Albert-László Barabási; Marc Vidal
Journal:  Nat Biotechnol       Date:  2007-10       Impact factor: 54.908

Review 4.  Global vision of druggability issues: applications and perspectives.

Authors:  Hiba Abi Hussein; Colette Geneix; Michel Petitjean; Alexandre Borrel; Delphine Flatters; Anne-Claude Camproux
Journal:  Drug Discov Today       Date:  2016-12-06       Impact factor: 7.851

5.  Genome-scale CRISPR-Cas9 knockout screening in human cells.

Authors:  Ophir Shalem; Neville E Sanjana; Ella Hartenian; Xi Shi; David A Scott; Tarjei Mikkelson; Dirk Heckl; Benjamin L Ebert; David E Root; John G Doench; Feng Zhang
Journal:  Science       Date:  2013-12-12       Impact factor: 47.728

Review 6.  Cornerstones of CRISPR-Cas in drug discovery and therapy.

Authors:  Christof Fellmann; Benjamin G Gowen; Pei-Chun Lin; Jennifer A Doudna; Jacob E Corn
Journal:  Nat Rev Drug Discov       Date:  2016-12-23       Impact factor: 84.694

7.  DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Authors:  David S Wishart; Craig Knox; An Chi Guo; Savita Shrivastava; Murtaza Hassanali; Paul Stothard; Zhan Chang; Jennifer Woolsey
Journal:  Nucleic Acids Res       Date:  2006-01-01       Impact factor: 16.971

8.  Is NMR Fragment Screening Fine-Tuned to Assess Druggability of Protein-Protein Interactions?

Authors:  David M Dias; Inge Van Molle; Matthias G J Baud; Carles Galdeano; Carlos F G C Geraldes; Alessio Ciulli
Journal:  ACS Med Chem Lett       Date:  2013-11-03       Impact factor: 4.345

9.  A systematic approach to identify novel cancer drug targets using machine learning, inhibitor design and high-throughput screening.

Authors:  Jouhyun Jeon; Satra Nim; Joan Teyra; Alessandro Datti; Jeffrey L Wrana; Sachdev S Sidhu; Jason Moffat; Philip M Kim
Journal:  Genome Med       Date:  2014-07-30       Impact factor: 11.117

10.  The InterPro protein families database: the classification resource after 15 years.

Authors:  Alex Mitchell; Hsin-Yu Chang; Louise Daugherty; Matthew Fraser; Sarah Hunter; Rodrigo Lopez; Craig McAnulla; Conor McMenamin; Gift Nuka; Sebastien Pesseat; Amaia Sangrador-Vegas; Maxim Scheremetjew; Claudia Rato; Siew-Yit Yong; Alex Bateman; Marco Punta; Teresa K Attwood; Christian J A Sigrist; Nicole Redaschi; Catherine Rivoire; Ioannis Xenarios; Daniel Kahn; Dominique Guyot; Peer Bork; Ivica Letunic; Julian Gough; Matt Oates; Daniel Haft; Hongzhan Huang; Darren A Natale; Cathy H Wu; Christine Orengo; Ian Sillitoe; Huaiyu Mi; Paul D Thomas; Robert D Finn
Journal:  Nucleic Acids Res       Date:  2014-11-26       Impact factor: 16.971

View more
  18 in total

Review 1.  The PROTACtable genome.

Authors:  Melanie Schneider; Chris J Radoux; Andrew Hercules; David Ochoa; Ian Dunham; Lykourgos-Panagiotis Zalmas; Gerhard Hessler; Sven Ruf; Veerabahu Shanmugasundaram; Michael M Hann; Pam J Thomas; Markus A Queisser; Andrew B Benowitz; Kris Brown; Andrew R Leach
Journal:  Nat Rev Drug Discov       Date:  2021-07-20       Impact factor: 84.694

2.  The Cancer Surfaceome Atlas integrates genomic, functional and drug response data to identify actionable targets.

Authors:  Zhongyi Hu; Jiao Yuan; Meixiao Long; Junjie Jiang; Youyou Zhang; Tianli Zhang; Mu Xu; Yi Fan; Janos L Tanyi; Kathleen T Montone; Omid Tavana; Ho Man Chan; Xiaowen Hu; Robert H Vonderheide; Lin Zhang
Journal:  Nat Cancer       Date:  2021-12-13

Review 3.  Impact of the Protein Data Bank on antineoplastic approvals.

Authors:  John D Westbrook; Rose Soskind; Brian P Hudson; Stephen K Burley
Journal:  Drug Discov Today       Date:  2020-02-14       Impact factor: 7.851

4.  Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Authors:  Fiona M Behan; Francesco Iorio; Gabriele Picco; Kosuke Yusa; Mathew J Garnett; Emanuel Gonçalves; Charlotte M Beaver; Giorgia Migliardi; Rita Santos; Yanhua Rao; Francesco Sassi; Marika Pinnelli; Rizwan Ansari; Sarah Harper; David Adam Jackson; Rebecca McRae; Rachel Pooley; Piers Wilkinson; Dieudonne van der Meer; David Dow; Carolyn Buser-Doepner; Andrea Bertotti; Livio Trusolino; Euan A Stronach; Julio Saez-Rodriguez
Journal:  Nature       Date:  2019-04-10       Impact factor: 49.962

5.  Large scale meta-analysis of preclinical toxicity data for target characterisation and hypotheses generation.

Authors:  Jordi Munoz-Muriedas
Journal:  PLoS One       Date:  2021-06-08       Impact factor: 3.240

6.  Assessing drug target suitability using TargetMine.

Authors:  Yi-An Chen; Erika Yogo; Naoko Kurihara; Tomoshige Ohno; Chihiro Higuchi; Masatomo Rokushima; Kenji Mizuguchi
Journal:  F1000Res       Date:  2019-02-28

Review 7.  Advances in Genomics for Drug Development.

Authors:  Roberto Spreafico; Leah B Soriaga; Johannes Grosse; Herbert W Virgin; Amalio Telenti
Journal:  Genes (Basel)       Date:  2020-08-15       Impact factor: 4.096

Review 8.  Impact of structural biologists and the Protein Data Bank on small-molecule drug discovery and development.

Authors:  Stephen K Burley
Journal:  J Biol Chem       Date:  2021-03-17       Impact factor: 5.157

9.  Genome-wide CRISPR screens of oral squamous cell carcinoma reveal fitness genes in the Hippo pathway.

Authors:  Pei San Yee; Stacey Price; Annie Wai Yeeng Chai; Shi Mun Yee; Hui Mei Lee; Vivian Kh Tiong; Emanuel Gonçalves; Fiona M Behan; Jessica Bateson; James Gilbert; Aik Choon Tan; Ultan McDermott; Mathew J Garnett; Sok Ching Cheong
Journal:  Elife       Date:  2020-09-29       Impact factor: 8.140

10.  Open Targets Platform: supporting systematic drug-target identification and prioritisation.

Authors:  David Ochoa; Andrew Hercules; Miguel Carmona; Daniel Suveges; Asier Gonzalez-Uriarte; Cinzia Malangone; Alfredo Miranda; Luca Fumis; Denise Carvalho-Silva; Michaela Spitzer; Jarrod Baker; Javier Ferrer; Arwa Raies; Olesya Razuvayevskaya; Adam Faulconbridge; Eirini Petsalaki; Prudence Mutowo; Sandra Machlitt-Northen; Gareth Peat; Elaine McAuley; Chuang Kee Ong; Edward Mountjoy; Maya Ghoussaini; Andrea Pierleoni; Eliseo Papa; Miguel Pignatelli; Gautier Koscielny; Mohd Karim; Jeremy Schwartzentruber; David G Hulcoop; Ian Dunham; Ellen M McDonagh
Journal:  Nucleic Acids Res       Date:  2021-01-08       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.